|Full Name||von Hippel-Lindau tumor suppressor|
|Product Description||Rabbit Polyclonal antibody to Von Hippel Lindau (von Hippel-Lindau tumor suppressor)|
|Background||Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq]|
|Synonyms||HRCA1 antibody, RCA1 antibody, VHL1 antibody, VHL antibody, pVHL antibody, elongin binding protein antibody, protein G7 antibody, von Hippel-Lindau disease tumor suppressor antibody, von Hippel-Lindau tumor suppressor antibody|
|Cellular Localization||Isoform 1: Cytoplasm , Membrane; Peripheral membrane protein , Nucleus , Isoform 3: Cytoplasm |
|Immunogen||Recombinant protein encompassing a sequence within the center region of human VHL. The exact sequence is proprietary.|
|Species Reactivity||Human, Mouse, Rat|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.
|Predict Reactivity Note||Dog (93%), Bovine (80%)|